Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Visen Pharma Closes $150 Million Financing for Endocrine Drugs

publication date: Jan 12, 2021

Shanghai's Visen Pharma closed a $150 million Series B financing to develop novel endocrine drugs in a round led by Sequoia China. In 2018, Visen was formed by Ascendis Pharma A/S of Denmark and an investor syndicate led by Vivo Capital and Sofinnova that contributed $40 million in capital for a 50% stake. The company's pipeline consists of three clinical-stage Ascendis-developed rare disease therapies for endocrinology indications including growth hormone deficiency. More details....

Stock Symbol: (NSDQ: ASND)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.